Reuland, Danielle Judith, authorHamilton, Karyn L., advisorMiller, Benjamin F., committee memberFrye, Melinda A., committee member2007-01-032007-01-032010http://hdl.handle.net/10217/37876Department Head: Richard Gay Israel.Increased production of reactive oxygen species has been implicated in the pathogenesis of cardiovascular disease (CVD), with enhanced endogenous antioxidants proposed as a potential mechanism for promoting redox balance. Protandim is a well-defined combination of five widely studied medicinal plants derived from botanical sources [Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)]. The purpose of this study was to determine if treatment of cardiomyocytes with Protandim induces phase II detoxification enzymes, including the endogenous antioxidant heme oxygenase-1 (HO-1), with activation of nuclear factor E2 p45-related factor 2 (Nrf2), and protection from oxidative stress induced apoptosis. In cultured cardiomyocytes, treatment with Protandim was associated with activation of Nrf2 and a significant increase in HO-1. Protandim supplemented cells were protected against hydrogen peroxide-induced apoptosis as assessed by TUNEL (35% apoptotic in untreated vs. 5% apoptotic in Protandim treated). These findings support the use of Protandim as a potential method for upregulation of antioxidant defenses and protection of heart cells against an oxidative challenge. Future studies will focus on optimizing phytochemical induction of Nrf2-mediated antioxidant defenses in relevant in vivo models of CVD.masters thesesengCopyright and other restrictions may apply. User is responsible for compliance with all applicable laws. For information about copyright law, please see https://libguides.colostate.edu/copyright.Text